Thrombotic Thrombocytopenic Purpura: Symptoms and Treatment
Updated: 3 days ago
Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026
Thrombotic thrombocytopenic purpura, or TTP, is a rare blood disorder in which blood clots form in small blood vessels throughout the body. These clots can restrict oxygen-rich blood flow to vital organs, including the brain, kidneys, and heart. [1]
TTP comes on quickly, does not improve on its own, and can be life-threatening without treatment. Suspected TTP is a medical emergency. Do not wait for a routine appointment. Seek immediate emergency medical care. [1]
Quick Answer: What is thrombotic thrombocytopenic purpura?
Thrombotic thrombocytopenic purpura (TTP) is a rare disorder in which small blood clots form throughout the body's small blood vessels, blocking blood flow to organs and using up platelets. A shortage of the ADAMTS13 enzyme is central. It can cause confusion, fatigue, jaundice and skin spots. TTP always needs treatment; if suspected, go to an emergency room. [1]
What the research says
Caplacizumab speeds platelet recovery and lowers recurrence. In a double-blind trial of 145 patients with acquired TTP receiving plasma exchange, median time to platelet normalization was 2.69 days with caplacizumab versus 2.88 days with placebo (P = 0.01). A composite of TTP-related death, recurrence, or thromboembolic event occurred in 12% versus 49% (P < 0.001), and recurrence at any time in 12% versus 38% (P < 0.001). Mucocutaneous bleeding was the most common adverse event (65% versus 48%) (Scully et al., N Engl J Med, 2019). [2]
Monitoring ADAMTS13 and treating early may reduce clinical relapses. In a UK review of 443 patients with immune-mediated TTP, relapse occurred in 40% at 5 years of follow-up. Clinical relapse rates were lower in the later period, with regular monitoring and preemptive rituximab (11.1% versus 22.6%, P = 0.0004), and 96% of ADAMTS13 relapses responded to anti-CD20 therapy (Doyle et al., Blood, 2023). [3]
What do the words in TTP mean?
The name describes several features of the condition. Thrombotic refers to the blood clots, or thrombi, that develop. Thrombocytopenic means that the blood has a reduced number of platelets. Purpura refers to purplish dots and bruises caused by bleeding beneath the skin. [1]
In TTP, platelets are used up making clots that the body does not need. That can leave fewer platelets available to help stop bleeding when a blood vessel is injured. [1]
What happens in TTP?
TTP involves low activity of the ADAMTS13 enzyme. ADAMTS13 normally helps prevent platelets from forming unnecessary clots. When there is not enough working enzyme, clots can form in small blood vessels throughout the body. [1]
Red blood cells may break apart when they collide with these clots. This contributes to anemia, while the use of platelets in unnecessary clots contributes to thrombocytopenia. [1]
How is acquired thrombotic thrombocytopenic purpura different from inherited TTP?
Acquired TTP can flare with HIV, lupus, pregnancy or certain medications such as chemotherapy, cyclosporine A and quinine, though not every trigger is known. [1]
Type | What it means |
Acquired TTP | The most common type, also called immune-mediated TTP. The immune system mistakenly makes antibodies that interfere with ADAMTS13 activity. |
Inherited TTP | A rare type caused when both biological parents pass down a faulty gene affecting the ADAMTS13 enzyme. Symptoms often begin during pregnancy or when the body is under stress. |
Some people experience flares associated with HIV, lupus, pregnancy, or certain medications such as chemotherapy, cyclosporine A, and quinine. Experts are not sure what triggers every episode. [1]
What are the symptoms of TTP?
Thrombotic thrombocytopenic purpura (TTP) usually develops quickly, with steady, noticeable symptoms that often affect the brain first, though clots can affect any organ. Symptoms tend to be steady and noticeable rather than coming and going. The brain is often one of the first organs affected, but clots can affect any organ. Possible symptoms include:
Symptom or sign | What it may look or feel like |
Altered mental status or confusion | Changes in alertness, thinking, or awareness. |
Headache | Pain that may occur with other neurologic symptoms. |
Fatigue | Unusual tiredness or reduced energy. |
Nausea and vomiting | Digestive symptoms that may accompany the illness. |
Pale or yellowing skin | Pallor or jaundice. |
Shortness of breath | Difficulty breathing or feeling breathless. |
Petechiae | Tiny red or purple dots beneath the skin. |
Blood in the urine | Urine that contains blood. |
Vision changes | Blurred or double vision. |
These symptoms do not prove that someone has TTP. They require urgent professional assessment when TTP is a possibility, especially because the condition can affect the brain, heart, kidneys, and other organs.
Why is thrombotic thrombocytopenic purpura (TTP) a medical emergency?
TTP can block blood flow to vital organs. Possible complications include brain damage, heart attack, kidney dysfunction, pregnancy loss, seizure, and stroke. Clots in the heart may also cause dangerous heart rhythms.
TTP does not improve on its own and always needs treatment. If you are experiencing a concerning combination of symptoms or a healthcare professional suspects TTP, go to an emergency room immediately rather than waiting for a routine appointment. [1]
How is TTP diagnosed?
A healthcare provider begins with a physical exam and questions about symptoms and health history. If TTP is suspected, blood and urine tests help evaluate the enzyme activity, blood-cell changes, organ effects, and evidence of red blood cell breakdown. [1]
Test | What it helps evaluate |
ADAMTS13 assay | Measures ADAMTS13 enzyme activity. Low levels confirm a TTP diagnosis. |
Complete blood count | Counts blood cells and may show lower red blood cell and platelet levels. |
Peripheral blood smear | Examines blood under a microscope; broken or torn red blood cells called schistocytes may be present. |
Bilirubin test | Measures a waste product of damaged red blood cells; levels may be high. |
Kidney-function tests | Evaluate kidney function; urine may contain blood cells or protein. |
Lactate dehydrogenase test | Measures LDH, an enzyme released when tissues are damaged; TTP can raise LDH levels. |
Testing and treatment may happen at the same time because immediate care is critical when TTP is suspected. [1]
How is TTP treated?
TTP treatment takes place in a hospital. Plasma therapy is the most common approach, and medication may be added depending on the type and severity of TTP. [1]
Plasma therapy
Plasma exchange replaces abnormal plasma with healthy donor plasma. It is a life-saving treatment for acquired TTP. Corticosteroids may be used during an acute episode to reduce symptoms and inflammation. [1]
Plasma therapy continues until symptoms improve. This may take days or weeks. [1]
Medicines
Medicine or treatment | Role described in care |
Glucocorticoids | Suppress immune activity and may benefit people with TTP. |
Caplacizumab | Treats acute TTP by raising platelet counts faster than plasma exchange alone, which can lead to quicker remission. |
Rituximab | Can help prevent relapse after treatment with corticosteroids and plasma exchange. |
Recombinant ADAMTS13 | Replaces the ADAMTS13 enzyme and is FDA-approved to prevent or treat episodes of the inherited form of TTP. Its use in immune-mediated TTP continues to be studied. |
Surgery
In rare cases, a provider may recommend removing the spleen, called a splenectomy. This may be considered when severe TTP does not respond to treatment or keeps coming back. [1]
How long does recovery take?
Recovery depends on the severity of TTP and the treatment used. Most people who receive plasma therapy need several days to a few weeks. People who have a splenectomy usually need about four to six weeks to recover.
Recovery is not only about how a person feels immediately after treatment. Because TTP can relapse, follow-up with a hematologist and regular monitoring are important after an acute episode.
Can TTP come back?
Yes. Relapses can happen after treatment. Close contact with a hematologist helps the care team monitor for changes and plan follow-up. [1]
Regular ADAMTS13 testing may identify a drop in enzyme activity before symptoms return. If the level falls, preventive treatment with rituximab may help stop a relapse before it starts. [1]
What is the outlook for TTP?
TTP used to be fatal, but fast treatment has substantially improved outcomes. Cleveland Clinic reports that without treatment only about 1 in 10 people with TTP survives, while with proper care survival rises to 8 or 9 out of 10 people. [1]
Many people with proper care lead normal lives. The outlook for an individual depends on the type of TTP, the severity of the episode, complications, response to treatment, and follow-up care. Population survival figures cannot predict what will happen to one person. [1]
When should you seek help?
TTP symptoms are serious enough to require emergency evaluation. Do not wait for a routine appointment if TTP is suspected. Immediate treatment is critical, and acute TTP requires hematology and intensive-care expertise.
Contact emergency services or go to an emergency department for urgent assessment if symptoms such as confusion, altered mental status, severe or unusual headache, vision changes, shortness of breath, jaundice, unexplained purple skin spots, blood in the urine, or other rapidly developing concerns could fit TTP.
What questions should you ask after a thrombotic thrombocytopenic purpura diagnosis?
Question | Why it may help |
Is my TTP acquired or inherited? | Clarifies the type and may affect treatment and family discussions. |
What does my ADAMTS13 result mean? | Explains enzyme activity and how it relates to relapse monitoring. |
Which blood tests will be repeated? | Helps you understand how platelets, red blood cells, kidney function, and other markers are tracked. |
How long may plasma therapy take? | Gives context for hospital care and recovery planning. |
Which medicines are part of my treatment? | Helps clarify why corticosteroids, caplacizumab, rituximab, or recombinant ADAMTS13 may be used. |
What symptoms should trigger emergency care? | Creates a clear plan for possible recurrence. |
How often will ADAMTS13 be monitored? | Supports early detection of changes before symptoms return. |
Conclusion: fast treatment and follow-up matter
Thrombotic thrombocytopenic purpura is a rare blood disorder in which small-vessel blood clots can restrict oxygen-rich blood flow to vital organs. Low ADAMTS13 activity allows unnecessary platelet clots to form, uses up platelets, and can contribute to red blood cell breakdown. [1]
TTP can cause confusion, headache, fatigue, nausea, jaundice, shortness of breath, petechiae, blood in the urine, and vision changes. It comes on quickly, does not improve on its own, and can be life-threatening without treatment. [1]
Treatment takes place in a hospital and commonly includes plasma exchange, medicines, and sometimes surgery. Relapses can happen, so hematology follow-up and ADAMTS13 monitoring remain important after the acute episode. [1]
Continue exploring plain-language health education: visit the health blog. For broader information about blood disorders, see the MedlinePlus blood disorders overview. If TTP is suspected now, seek emergency medical care rather than browsing for more information. [1]
Frequently Asked Questions
What is TTP in simple terms?
TTP is a rare blood disorder in which blood clots form in small blood vessels throughout the body. The clots can restrict blood flow to organs and use up platelets.
Is TTP an emergency?
Yes. TTP comes on quickly, does not improve on its own, and can be life-threatening without treatment. Suspected TTP needs immediate emergency evaluation.
What causes TTP?
TTP occurs when there is not enough working ADAMTS13 enzyme activity. Acquired TTP happens when antibodies interfere with the enzyme. Inherited TTP occurs when both biological parents pass down a faulty gene affecting ADAMTS13.
What are the first symptoms of TTP?
Symptoms vary, but possible signs include confusion or altered mental status, headache, fatigue, nausea and vomiting, pale or yellowing skin, shortness of breath, tiny red or purple skin spots, blood in the urine, and blurred or double vision.
What is ADAMTS13?
ADAMTS13 is an enzyme that helps prevent platelets from forming unnecessary blood clots. Low activity can allow clots to develop in small blood vessels.
How is TTP diagnosed?
Diagnosis may involve a physical exam, health-history review, ADAMTS13 assay, complete blood count, peripheral blood smear, bilirubin test, kidney-function tests, and lactate dehydrogenase testing.
What is the main treatment for TTP?
Hospital-based plasma therapy is commonly used. Plasma exchange replaces abnormal plasma with healthy donor plasma. Corticosteroids and other medicines may also be used.
How long does TTP treatment take?
Plasma therapy may take several days to a few weeks, depending on the person’s condition and response. Recovery after a splenectomy usually takes about four to six weeks.
Can TTP relapse?
Yes. Relapses can occur. Close hematology follow-up and regular ADAMTS13 monitoring can help identify changes early.
Can TTP be inherited?
Yes. Inherited TTP is rare and occurs when both biological parents pass down a faulty gene affecting ADAMTS13. Symptoms often begin during pregnancy or when the body is under stress.
What should I do if I think I have TTP?
Do not wait for a routine appointment. Go to an emergency department or contact emergency services for immediate evaluation, especially if symptoms are developing quickly or include confusion, vision changes, shortness of breath, unusual bruising or purple spots, jaundice, or blood in the urine.
Related Reading
References
Cleveland Clinic. Thrombotic Thrombocytopenic Purpura. Cleveland Clinic. Last updated May 5, 2025. https://my.clevelandclinic.org/health/diseases/22380-thrombotic-thrombocytopenic-purpura
Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335-346. PMID 30625070. https://doi.org/10.1056/NEJMoa1806311
Doyle AJ, Stubbs MJ, Dutt T, et al. Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy. Blood. 2023;141(3):285-294. PMID 36322971. https://doi.org/10.1182/blood.2022017023
National Library of Medicine. Blood Disorders. MedlinePlus. Last updated October 14, 2024. https://medlineplus.gov/blooddisorders.html
Disclaimer
This article is for general educational purposes and is not a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of a qualified health provider with any questions you may have regarding a medical condition.
This article is not a diagnosis, emergency protocol, prescription or individualized treatment plan. No individual symptom proves TTP. Do not use watchful waiting or home management for suspected TTP; seek immediate emergency evaluation and qualified hematology follow-up after diagnosis.
Comments